NORTHWEST BIOTHERAPEUTICS INC cotiza a 0.16 USD y tiene una capitalización bursátil de $278M. En los últimos 12 meses ha facturado $2M con un margen de flujo de caja libre del -3357.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its l…
| Periodo | 2026-08 | 2017-04 | 2016-11 | 2016-08 |
|---|---|---|---|---|
| Real | — | $-0.34 | $-0.25 | $-0.20 |
| Estimado | — | $-0.19 | $-0.12 | $-0.29 |
| Sorpresa | — | -78.9% | -108.3% | +31.0% |
| Métrica | NWBO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -4347.9% | -38.6% | -4309.3% |
| Net Margin | -4365.9% | -33.6% | -4332.3% |
| FCF Margin | -3357.6% | -13.9% | -3343.7% |
| ROE | — | -40.4% | — |
| ROA | -74.0% | -32.0% | -42.0% |
| Current Ratio | 0.06 | 2.84 | -2.78 |
| Debt / Equity | -1.00 | 0.28 | -1.28 |